GlassScriptPhysician profile
Antonio T Fojo
NPI 1821212473
$35,717.20
in general payments reported to CMS, 2019-2025
13 companies · $6,799 in 2025
The $6,799 reported for 2025 was more than what 77% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2021: $9,625 · 2022: $8,737 · 2023: $9,297 · 2024: $829 · 2025: $6,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,257 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,799 · Consulting Fee: $728 · Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,256.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,798.96 |
| Consulting Fee | $727.50 |
| Food and Beverage | $141.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,663.69 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $6,798.96 | 2025 | |
| Merck Sharp & Dohme LLC | $6,643.81 | 2021-2023 | Keytruda |
| Tg Therapeutics, INC. | $6,412.50 | 2022 | |
| Hra Pharma Rare Diseases | $3,000.00 | 2021 | |
| Progenics Pharmaceuticals, INC. | $1,887.50 | 2022 | |
| Daiichi Sankyo INC. | $828.75 | 2024 | |
| Genzyme Corporation | $429.95 | 2019 | |
| Amgen INC. | $30.34 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.70 | 2023 | Somatuline Depot, Onivyde |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Fojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.